Login to Your Account

Cortex's Ampakine CX516 Fizzles, But More Potent Ones In Pipeline

By Randall Osborne

Wednesday, February 18, 2004
Cortex Pharmaceuticals Inc.'s CX516 for mild cognitive impairment failed to meet its primary endpoint in a Phase IIb trial, although a subset of patients with the worst memory trouble showed improvement over placebo. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription